 |
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 3
Jul 27, 2010
|
8.7 KB |
|
| |
SAN DIEGO, July 27, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report second quarter 2010 financial results after the NASDAQ Global Market closes on Tuesday, August 3, 2010. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena...
|
|
New England Journal of Medicine Publishes Results of Two-Year BLOOM Trial Showing Lorcaserin Caused Significant Weight Loss and Improved Maintenance of Weight Loss
Jul 14, 2010
|
13.4 KB |
|
| |
SAN DIEGO and WOODCLIFF LAKE, N.J., July 14, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. today announced that results from the two-year BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial will be published in the July 15, 2010, issue of the New England...
|
|
Eisai to Market Arena Pharmaceuticals' Lorcaserin for Obesity and Weight Management in U.S. Following FDA Approval
Jul 1, 2010
|
13.9 KB |
|
| |
SAN DIEGO, July 1, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmace...
|
|
Arena Pharmaceuticals' Lorcaserin Reduces Body Weight and Improves Cardiovascular Risk Factors Across Patient Subgroups
Jun 26, 2010
|
10.1 KB |
|
| |
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined...
|
|
Arena Pharmaceuticals' Lorcaserin to Be Featured in Presentations at the American Diabetes Association's 70th Scientific Sessions
Jun 17, 2010
|
10.2 KB |
|
| |
SAN DIEGO, June 17, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that new data analyses from lorcaserin's pivotal Phase 3 clinical trial program will be presented in poster sessions at the American Diabetes Association's 70th Scientific Sessions in Orlando, Florida. The two posters highligh...
|
|
Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
Jun 4, 2010
|
8.4 KB |
|
| |
SAN DIEGO, June 4, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide an overview of the company at two upcoming investor conferences in New York City:
-- Jefferies 2010 Global Life Sciences Conferen...
|
|
Arena Pharmaceuticals to Receive $35.5 Million from Deerfield Management
Jun 3, 2010
|
8.7 KB |
|
| |
SAN DIEGO, June 3, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with Deerfield Management, a leading healthcare investment organization, to provide Arena with approximately $35.5 million through an equity investment.
Under the terms of this financing, ...
|
|
Arena Pharmaceuticals Announces Notification of Tentative September 16th FDA Advisory Committee Meeting to Review Lorcaserin for Weight Management
Jun 2, 2010
|
9.9 KB |
|
| |
SAN DIEGO, June 2, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the US Food and Drug Administration (FDA) has notified the company of the tentative scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New...
|
|
Arena Pharmaceuticals Announces First Quarter 2010 Financial Results and Recent Developments
May 7, 2010
|
14.5 KB |
|
| |
SAN DIEGO, May 7, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the first quarter ended March 31, 2010.
Arena reported a lower net loss in the first quarter of 2010 of $31.3 million, or $0.33 per share, compared to a net loss in the first quarter of 2009 of $50.6 millio...
|
|
Arena Pharmaceuticals to Present at the Ninth Annual JMP Securities Research Conference
May 6, 2010
|
8.4 KB |
|
| |
SAN DIEGO, May 6, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Ninth Annual JMP Securities Research Conference on Tuesday, May 11, 2010, at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) at The Ritz-Carlton in San Francisco. Robert E. Hoffma...
|
|
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, May 7, 2010
Apr 30, 2010
|
8.5 KB |
|
| |
SAN DIEGO, April 30, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first quarter 2010 financial results before the NASDAQ Global Market opens on Friday, May 7, 2010. That same morning, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vic...
|
|
Arena Pharmaceuticals to Present at the Deutsche Bank 35th Annual Health Care Conference
Apr 28, 2010
|
8.4 KB |
|
| |
SAN DIEGO, April 28, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Deutsche Bank 35th Annual Health Care Conference on Monday, May 3, 2010, at 11:20 a.m. Eastern Time (8:20 a.m. Pacific Time) at the InterContinental Boston Hotel in Boston. Jack...
|
|
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of APD916 for Narcolepsy and Cataplexy
Mar 24, 2010
|
9.5 KB |
|
| |
SAN DIEGO, March 24, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of patient screening in a Phase 1 clinical trial of APD916, a novel oral drug candidate discovered by Arena that targets the histamine H3 receptor for the treatment of narcolepsy and cataplexy.
"There is a nee...
|
|
Arena Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
Mar 18, 2010
|
8.3 KB |
|
| |
SAN DIEGO, March 18, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Barclays Capital 2010 Global Healthcare Conference on Tuesday, March 23, 2010, at 5:15 p.m. Eastern Time (2:15 p.m. Pacific Time) at the Loews Miami Beach Hotel in Miami, Florid...
|
|
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2009 Financial Results
Mar 12, 2010
|
20.2 KB |
|
| |
SAN DIEGO, March 12, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the fourth quarter and full year ended December 31, 2009.
Arena reported a lower net loss allocable to common stockholders in the fourth quarter of 2009 of $29.8 million, or $0.32 per share, compared to ...
|
|
Arena Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
Mar 8, 2010
|
8.3 KB |
|
| |
SAN DIEGO, March 8, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the Cowen and Company 30th Annual Health Care Conference on Wednesday, March 10, 2010, at 8:45 a.m. Eastern Time (5:45 a.m. Pacific Time) at the Boston Marriott Copley Place in Bosto...
|
|
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Friday, March 12, 2010
Mar 8, 2010
|
8.5 KB |
|
| |
SAN DIEGO, March 8, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report fourth quarter and full year 2009 financial results before the NASDAQ Global Market opens on Friday, March 12, 2010. That same morning, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hof...
|
|
Arena Pharmaceuticals Receives PDUFA Date for Lorcaserin NDA
Feb 26, 2010
|
9.8 KB |
|
| |
SAN DIEGO, Feb. 26, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the US Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) date of October 22, 2010, for the review of the lorcaserin New Drug Application (NDA). The acceptance of the lorcaserin NDA ...
|
|
Arena Pharmaceuticals Announces FDA Acceptance of Lorcaserin NDA for Filing
Feb 24, 2010
|
9.6 KB |
|
| |
SAN DIEGO, Feb. 24, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that its New Drug Application (NDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss, has been accepted for filing by the U...
|
|
Arena Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Feb 4, 2010
|
8.2 KB |
|
| |
SAN DIEGO, Feb. 4, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2010 at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time) at the Waldorf=Astoria Hotel in New York City. Jack Lief...
|
|
|
